Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2021-01-22

Clinical Trial Update: Riociguat rEplacing PDE-5i Therapy evaLuated Against Continued PDE-5i thErapy [Phase 4]

View source ↗

Summary

Phase 4 trial comparing riociguat to PDE-5 inhibitor therapy in pulmonary arterial hypertension has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Riociguat (riociguat)

Snippet

Sponsor: Bayer | Conditions: Pulmonary Arterial Hypertension | Phase 4 | Status: COMPLETED | Results posted: 2021-01-22